Sinopec Posts 36.8% Net Profit Drop in 2025 Amid Weak Petrochemical Margins and Energy Transition Pressures 
OpenAI's Desktop Superapp: Unifying ChatGPT, Codex, and Browser Tools for Enterprise AI 
Oil Prices Surge Amid Trump's Iran Ultimatum Over Strait of Hormuz 
Apple Defies China's Smartphone Slump with Strong Early 2026 Sales 
U.S. Appeals Court Strikes Down FTC Order Against TurboTax "Free" Advertising 
Asian Markets Mixed as Oil Volatility and Inflation Fears Weigh on Sentiment 
Amazon's "Transformer" Phone: Can It Succeed Where Fire Phone Failed? 
Gold Prices Extend Losing Streak, On Track for Worst Weekly Loss Since 1983 
Jeff Bezos Eyes $100 Billion Fund to Transform Manufacturing With AI 
Dollar Weakens as Middle East War Reshapes Global Rate Expectations 
Goldman Sachs Delays Bank of England Rate Cut Forecast Amid Middle East Inflation Risks 
China Holds Benchmark Loan Prime Rate Steady for Tenth Consecutive Month 
EA's $15B Debt Offering Draws $25B in Investor Demand Amid Credit Market Turmoil 
Federal Reserve Crisis: DOJ Standoff Threatens Powell's Succession and Rate Stability 
Iran-Israel War Escalates: Long-Range Missiles, Nuclear Site Strikes, and Global Energy Crisis 
Global Markets Tumble as US-Iran Tensions Escalate, Oil Surges 
NVIDIA's Feynman AI Chip May Face Redesign Amid TSMC Capacity Crunch 
Samsung Biologics and Novartis International AG signed a contract manufacturing organization deal, and this was announced on Tuesday, June 7. The deal is worth $81 million.
According to The Korea Herald, the South Korean biotech company signed an intent letter for the CMO with the Swiss multinational pharmaceutical corporation. The agreement was announced via Samsung Biologics’ regulatory filing that also revealed that the companies signed the initial contract late last week.
Based on the report, the amount of the contract is equivalent to 6.41% of Samsung Biologics’ annual sales last year, which reached KRW1.57 trillion or around $1.25 billion. Then again, it was not mentioned which of Novartis’ biopharmaceutical products Samsung Biologics is producing under the CMO agreement.
The Korean biotech firm said that it would be releasing more deals in the future after both parties signed the main contract for their CMO partnership. The collab is said to be the first time Samsung Biologics is securing a deal from the Swiss pharmaceutical company.
“The letter of intent was the first contract between the two firms,” an official of Samsung Biologics stated. “We look forward to continuing to have cooperative relations through this deal in the future.”
The Korea Economic Daily reported that the latest deal increased Samsung Biologics’ total for CMO contracts to $400 million. The company has so far won orders from other multinational pharma firms such as GSK plc that is formerly known as GlaxoSmithKline plc, and Eli Lilly & Co. this year. In comparison, the firm was able to secure $1 billion worth of CMO contracts in 2021.
The South Korean CMO drugmaker obtained contracts from the top pharmaceutical firms in the world, including Bristol Myers Squibb, Roche, Johnson & Johnson, and Merck & Co. It was added that Samsung Biologics also has a contract with Gilead Sciences Inc. in the US.
Meanwhile, Samsung Biologics has been mostly manufacturing antibody treatments recently instead of cell-gene therapy (CGT). It has built up production facilities to make the drug substance for the messenger ribonucleic acid (mRNA)-based COVID-19 vaccines in its plant.
